Skip to main content

Amphastar Pharmaceutical - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Amphastar Pharmaceuticals Inc. (ISIN: US03209R1032, WKN: A11664 ) Kursdatum: 21.07.2017 Kurs: 18,450 USD
Beschreibung Daten
Symbol AMPH
Marktkapitalisierung 876.448.768,00 USD
Land Vereinigte Staaten von Amerika
Indizes NO INDEX
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet ir.amphastar.com
Letztes Bilanz Update 15.03.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
51,02 22,73 0,00% 2,44 76,98 83,86 3,44 2,66

Firmenbeschreibung

 

 

20.  Quarterly Financial Data (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2015 Quarters

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

 

First

 

 

 

    

 

 

 

Second

 

 

 

    

 

 

 

Third

 

 

 

    

 

 

 

Fourth

 

 

 

 

 

 

 

 

 

Net revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finished pharmaceutical products

 

 

 

 

 

 

 

$

 

50,872

 

 

 

 

 

 

 

$

 

50,075

 

 

 

 

 

 

 

$

 

57,902

 

 

 

 

 

 

 

$

 

66,092

 

 

 

 

 

 

 

 

 

API

 

 

 

 

 

 

 

 

 

6,014

 

 

 

 

 

 

 

 

 

3,778

 

 

 

 

 

 

 

 

 

5,966

 

 

 

 

 

 

 

 

 

10,820

 

 

 

 

 

 

 

 

 

Total net revenues

 

 

 

 

 

 

 

$

 

56,886

 

 

 

 

 

 

 

$

 

53,853

 

 

 

 

 

 

 

$

 

63,868

 

 

 

 

 

 

 

$

 

76,912

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finished pharmaceutical products

 

 

 

 

 

 

 

$

 

12,853

 

 

 

 

 

 

 

$

 

12,634

 

 

 

 

 

 

 

$

 

19,302

 

 

 

 

 

 

 

$

 

29,357

 

 

 

 

 

 

 

 

 

API

 

 

 

 

 

 

 

 

 

427

 

 

 

 

 

 

 

 

 

684

 

 

 

 

 

 

 

 

 

(1,724)

 

 

 

 

 

 

 

 

 

3,814

 

 

 

 

 

 

 

 

 

Total gross profit

 

 

 

 

 

 

 

$

 

13,280

 

 

 

 

 

 

 

$

 

13,318

 

 

 

 

 

 

 

$

 

17,578

 

 

 

 

 

 

 

$

 

33,171

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

 

 

 

 

 

 

$

 

(665)

 

 

 

 

 

 

 

$

 

(6,647)

 

 

 

 

 

 

 

$

 

(3,008)

 

 

 

 

 

 

 

$

 

7,533

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares used to compute net income (loss) per share

 

 

 

 

 

 

 

 

 

 

Firmenstrategie

RevenueRecognitionPolicyTextBlock

SegmentReportingDisclosureTextBlock

 

 

6.  Segment Reporting

 

The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has established two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting.  The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:

 

 

 

 

·

 

 

 

Finished pharmaceutical products

 

 

 

·

 

 

 

Active pharmaceutical ingredients, or API

 

The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn®, Amphadase®, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin for external customers and internal product development.

Selected financial information by reporting segment is presented below:

 

EarningsPerSharePolicyTextBlock

 

 

5.  Income (Loss) per Share

 

Basic income (loss) per share is calculated based upon the weighted-average number of shares outstanding during the period and contingently issuable shares such as fully vested deferred stock units, or DSUs, and in 2015, such equity was issued as restricted stock units, or RSUs (such RSUs and DSUs are collectively referred to herein as RSUs), in addition to shares expected to be issued under the Company’s employee stock purchase plan, or ESPP, as of the date all necessary conditions for issuance have been met. Diluted income per share gives effect to all potential dilutive shares outstanding during the period, such as stock options, nonvested RSUs and shares issuable under the Company’s ESPP.

 

As the Company reported a net loss for the years ended December 31, 2015 and 2014, the diluted net loss per share, as reported, is equal to the basic net loss per share since the effect of the assumed exercise of stock options, vesting of nonvested RSUs, and issuance of common shares under the Company’s ESPP are anti-dilutive. Total stock options, nonvested RSUs, and shares issuable under the Company’s ESPP excluded from the year ended December 31, 2015 net loss per share were 12,240,467; 866,540, and 61,766, respectively. Total stock options and nonvested RSUs excluded from the year ended December 31, 2014 net loss per share were 11,371,891 and 503,010, respectively.    

 

For the year ended December 31, 2013, options to purchase 7,124,091 shares of stock with a weighted-average exercise price of $17.62 per share, respectively, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive. 

 

The following table provides the calculation of basic and diluted net income (loss) per share for each of the periods presented:

 

 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Year Ended December 31, 

 
 

 

 
 

 

 
 

 

 
 

2015

 
 

 

 
 

2014

 
 

 

 
 

2013

 
 

 

 
 

 

 
 

 

 
 

(in thousands)

 
 

 

 
 

Net revenues:

 
 

 

 
 

 

 
 

    

 
 

    

 
 

 

 
 

    

 
 

    

 
 

 

 
 

    

 
 

 

 
 

Finished pharmaceutical products

 
 

 

 
 

$

 
224,941 
 

 

 
 

$

 
198,480 
 

 

 
 

$

 
229,681 
 

 

 
 

API

 
 

 

 
 

 

 
26,578 
 

 

 
 

 

 
11,981 
 

 

 
 

 

 
 

 —

 
 

 

 
 

Total net revenues

 
 

 

 
 

 

 
251,519 
 

 

 
 

 

 
210,461 
 

 

 
 

 

 
229,681 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Gross Profit:

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Finished pharmaceutical products

 
 

 

 
 

 

 
74,146 
 

 

 
 

 

 
52,724 
 

 

 
 

 

 
86,956 
 

 

 
 

API

 
 

 

 
 

 

 
3,201 
 

 

 
 

 

 
(1,468) 
 

 

 
 

 

 
 

 —

 
 

 

 
 

Total gross profit

 
 

 

 
 

 

 
77,347 
 

 

 
 

 

 
51,256 
 

 

 
 

 

 
86,956 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Operating expenses

 
 

 

 
 

 

 
84,245 
 

 

 
 

 

 
69,239 
 

 

 
 

 

 
69,466 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Income (loss) from operations

 
 

 

 
 

 

 
(6,898) 
 

 

 
 

 

 
(17,983) 
 

 

 
 

 

 
17,490 
 

 

 
 

Non-operating income (expenses)

 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Year Ended December 31, 

 
 

 

 
 

 

 
 

 

 
 

2015

 
 

 

 
 

2014

 
 

 

 
 

2013

 
 

 

 
 

 

 
 

 

 
 

(in thousands, except per share data)

 
 

 

 
 

Basic and dilutive numerator:

 
 

 

 
 

 

 
 

    

 
 

    

 
 

 

 
 

    

 
 

    

 
 

 

 
 

    

 
 

 

 
 

Net income (loss)

 
 

 

 
 

$

 
(2,787) 
 

 

 
 

$

 
(10,699) 
 

 

 
 

$

 
11,862 
 

 

 
 

Denominator:

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Shares outstanding

 
 

 

 
 

 

 
44,961 
 

 

 
 

 

 
41,957 
 

 

 
 

 

 
38,705 
 

 

 
 

Contingently issuable shares – vested RSUs

 
 

 

 
 

 

 
 

 
 

 

 
 

 

 
 

 
 

 

 
 

 

 
 

 

 
 

Weighted-average shares outstanding — basic

 
 

 

 
 

 

 
44,961 
 

 

 
 

 

 
41,957 
 

 

 
 

 

 
38,712 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Net effect of dilutive securities:

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

 

 
 

Stock options

 
 

 

 
 

 

 
 

 —

 
 

 

 
 

 

 
 

 
 

 

 
 

 

 
104 
 

 

 
 

Contingently issuable shares – nonvested RSUs

 
 

 

 
 

 

 
 

 —

 
 

 

 
 

 

 
 

 
 

 

 
 

 

 
67 
 

 

 
 

Weighted-average shares outstanding — diluted

 
 

 

 
 

 

 
44,961 
 

 

 
 

 

 
41,957 
 

 

 
 

 

 
38,883 
 

 

 
 

Net income (loss) per share — basic

 
 

 

 
 

$

 
(0.06) 
 

 

 
 

$

 
(0.25) 
 

 

 
 

$

 
0.31 
 

 

 
 

Net income (loss) per share — diluted

 
 

 

 
 

$

 
(0.06) 
 

 

 
 

$

 
(0.25) 
 

 

 
 

$